FDA to phar­ma com­pa­nies: Us­ing CRO Synapse's stud­ies 'u­nac­cept­able'

The FDA is not hold­ing punch­es against In­dia-based CRO Synapse, say­ing that stud­ies con­duct­ed by the group are “un­ac­cept­able” due to da­ta in­tegri­ty is­sues and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.